Procept BioRobotics Corp (NASDAQ:PRCT) reported that Nouri Alaleh, serving as Executive Vice President, Chief Legal Officer, and Corporate Secretary, executed a transaction on June 8, 2026, involving the sale of 285 shares of the company's common stock. The total value of this divestment was calculated at $8,116, executed at a precise per-share price of $28.479. This specific transaction was not a discretionary market exit but was processed through the company's established sell-to-cover mechanism. The primary objective of this sale was to satisfy tax withholding obligations linked to the vesting of Restricted Stock Units (RSUs) that Alaleh received on June 5, 2026. Following the completion of this administrative divestment, Alaleh's direct holding of PROCEPT BioRobotics common stock stands at 105,069 shares.
The executive transaction coincides with a period of financial and clinical activity for the urological medical technology firm. PROCEPT BioRobotics recently delivered earnings results for the first quarter of 2026 that exceeded market expectations. The company reported an earnings per share (EPS) of $0.56, a substantial improvement that contrasted sharply with the anticipated figure of -$0.56. This performance represented a 200% surprise relative to forecasts. On the top line, revenue reached $83.13 million, surpassing the projected $80.5 million and marking a 3.27% revenue surprise. These financial metrics contribute to the company's broader twelve-month revenue total of $322 million, which reflects a 29% growth rate. The firm currently holds a market valuation of $1.64 billion.
From a clinical research perspective, Procept BioRobotics announced the completion of enrollment in its WATER IV randomized study, a pivotal component of its prostate cancer clinical program. The study successfully enrolled 280 patients and is designed to compare Aquablation therapy against radical prostatectomy. In addition to this enrollment milestone, the company secured FDA Investigational Device Exemption approval for a second randomized protocol within the same clinical program. Procept BioRobotics has scheduled the presentation of the primary endpoint results from the WATER IV study for the American Urological Association Annual Meeting in spring 2027.
Market data indicates that PRCT shares have experienced recent upward momentum, gaining 9.3% over the past week. Current trading data shows the stock at $29.09, reflecting a 0.31 point increase of 1.08% during closed trading. After-hours trading activity recorded a price of $29.09 with no additional movement. Some market analysis suggests the stock may be undervalued at current levels, trading below its estimated fair value. Investors seeking detailed valuation models can access comprehensive research reports that utilize industry-standard valuation frameworks to assess the equity.